Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1080/14760584.2021.1875824 http://scihub22266oqcxt.onion/10.1080/14760584.2021.1875824 33435774!7898300!33435774     free     free     free Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=33435774&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Expert+Rev+Vaccines 2021 ; 20 (1): 23-44 Nephropedia Template TP {{tp|p=33435774|t=2021. COVID-19 vaccine: where are we now and where should we go?|pdf=|usr=}}{{33435774}} gab.com Text COVID-19 vaccine: where are we now and where should we go JO: Expert Rev Vaccines http://www.kidney.de/pget.php?&tw=1&pmid=33435774 #FOAvip INTRODUCTION: The severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has currently caused the pandemic with a high progressive speed and has been considered as the global public health crisis in 2020. This new member of the coronavirus family has created a potentially fatal disease, called coronavirus disease-2019 (COVID-19). Despite the continuous efforts of researchers to find effective vaccines and drugs for COVID-19, there is still no success in this matter. AREAS COVERED: Here, the literature regarding the COVID-19 vaccine candidates currently in the clinical trials, as well as main candidates in pre-clinical stages for development and research, were reviewed. These candidates have been developed under five different major platforms, including live-attenuated vaccine, mRNA-based vaccine, DNA vaccines, inactivated virus, and viral-vector-based vaccine. EXPERT OPINION: There are several limitations in the field of the rapid vaccine development against SARS-CoV-2, and other members of the coronavirus family such as SARS-CoV and MERS-CoV. The key challenges of designing an effective vaccine within a short time include finding the virulence ability of an emerging virus and potential antigen, choosing suitable experimental models and efficient route of administration, the immune-response study, designing the clinical trials, and determining the safety, as well as efficacy. Twit Text FOAVip COVID-19 vaccine: where are we now and where should we go ????Expert Rev Vaccines http://www.kidney.de/pget.php?&tw=1&pmid=33435774 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33435774 #FOAvip English Wikipedia <ref>{{Cite pmid|33435774}}</ref> COVID-19 vaccine: where are we now and where should we go? #MMPMID33435774 Soleimanpour S; Yaghoubi A Expert Rev Vaccines 2021[Jan]; 20 (1): 23-44 PMID33435774show ga INTRODUCTION: The severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has currently caused the pandemic with a high progressive speed and has been considered as the global public health crisis in 2020. This new member of the coronavirus family has created a potentially fatal disease, called coronavirus disease-2019 (COVID-19). Despite the continuous efforts of researchers to find effective vaccines and drugs for COVID-19, there is still no success in this matter. AREAS COVERED: Here, the literature regarding the COVID-19 vaccine candidates currently in the clinical trials, as well as main candidates in pre-clinical stages for development and research, were reviewed. These candidates have been developed under five different major platforms, including live-attenuated vaccine, mRNA-based vaccine, DNA vaccines, inactivated virus, and viral-vector-based vaccine. EXPERT OPINION: There are several limitations in the field of the rapid vaccine development against SARS-CoV-2, and other members of the coronavirus family such as SARS-CoV and MERS-CoV. The key challenges of designing an effective vaccine within a short time include finding the virulence ability of an emerging virus and potential antigen, choosing suitable experimental models and efficient route of administration, the immune-response study, designing the clinical trials, and determining the safety, as well as efficacy. |Angiotensin-Converting Enzyme 2/metabolism[MESH] |Animals[MESH] |COVID-19 Vaccines/*administration & dosage/metabolism[MESH] |COVID-19/*epidemiology/metabolism/*prevention & control[MESH] |Clinical Trials as Topic/methods[MESH] |Humans[MESH] |SARS-CoV-2/*drug effects/metabolism[MESH]COVID-19 vaccine: where are we now and where should we go?(epmc).pdf DeepDyve Pubget Overpricing